Andres Poveda, MD, of Initia Oncology, discusses phase III results from the SOLO2 trial, which showed that, compared with placebo, maintenance olaparib improved median overall survival by 12.9 months in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Abstract 6002).
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate in previously treated patients with BRAF V600E–mutated metastatic colorectal cancer (Abstract 4001).
Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule. It showed early evidence of an acceptable safety profile, drug tolerability, and antileukemic activity, supporting further dose escalation in patients with acute myeloid leukemia (Abstract 7508).
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).
Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance and new format.
